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Production of monoclonal antibodies specific for human Tamm—
Horsfall protein. Fifteen monoclonal antibodies have been produced to
human Tamm—Horsfall protein (THP), identifying at least seven distinct
epitopes. The antibodies have been used to isolate from serum an
immunoreactive protein which comigrates with urinary THP. In addi-
tion, the antibodies may prove useful to set up an immunoenzymoassay
for urinary THP as well as for immunoaffinity purification.
Tamm—Horsfall protein (THP) is the most abundant protein
in normal urine, and the constituent of all tubular casts [1—3]. Its
synthesis and membrane expression by cells of the thick
ascending limb of the loop of Henle have led to the suggestion
that it might be involved in ion transfer [3, 4]. Recently Hoyer
et al [5—7] reported experimental studies demonstrating the
pathogenic role of active or passive anti-THP immunization.
However, the precise functions of THP and its role in human
pathology, although likely, are yet undefined. Further studies,
including analysis of extra—renal distribution and measurement
in body fluids (8—12), remain difficult partly because of the lack
of reliable immunological reagents. This led us to undertake the
production of monoclonal antibodies (Mab) specific for human
THP. We report here on the characterization of the specificities
obtained and their use to develop an immunoenzymoassay
(lEA) and to demonstrate the presence of THP in serum.
Methods
Preparation of human Tamrn—Horsfall protein
Tamm—Horsfall protein was prepared from normal human
urine by precipitation with 0.58 M NaCI as previously described
[2]. Purity was assessed by polyacrylamide gel electrophoresis
in the presence of SDS (PAGE—SDS) [13].
Production of monoclonal antibodies
Monoclonal antibodies were prepared according to methods
previously described [14, 15]. Supernatants were screened for
the presence of anti-THP antibodies by indirect immunofluo-
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rescence (hF) on frozen kidney sections and by lEA using THP
(200 ng in 200 piiter of carbonate bicarbonate buffer, pH 9.4)
adsorbed to plastic wells of microtiter plates (Nunc) by incuba-
tion for three hr at 37°C. After washing with PBS Tween 0.05%
(PBST), the wells were incubated for two hr at room tempera-
ture with 100 piiter of supernatant diluted one-half in PBST,
washed and incubated with peroxidase labeled sheep anti-
mouse IgG [15]. Enzyme activity was revealed with
Orthophenylenediamine (OPD). All supernatants considered as
positive reacted in the LEA and gave by hF the typical pattern
previously described [3]. Cell cloning, class and subclass deter-
mination of the Mab, purification and labeling with biotin were
performed as previously described [14—16].
Spec(/iciiy analysis of the Mab. In order to individualize the
epitopes identified by the various Mab, binding of a given biotin
labelled Mab (B-Mab) to solid phase THP was assessed in the
absence or in the presence of the Mab to be tested. Plastic wells
on which THP had been adsorbed as described above were
incubated with 100 .diter of supernatant or serial dilutions (10—2
to l0) in PBST of the ascites containing the Mab analyzed,
immediately followed by B-Mab (0.1 g/mliter) in PBST. Bind-
ing was compared to that observed with B-Mab diluted in PBST
only. Control experiments were performed with myeloma pro-
teins devoid of known antibody specificity. In all cases, solid
phase associated B-Mab was detected and quantified using
peroxidase labelled avidin (Vector Laboratories, Compiègne,
France) diluted 1/3000 in 50 m phosphate buffer pH 8.0
containing 0.5 M NaC1 and 0.5% Tween 20.
The ability to bind radiolabelled human THP was tested for
all Mab. THP was labelled with 125! by the chloramine T method
as described by Hartmann et al [17] to a specific activity of 70
ci/g. A constant amount of antibody was incubated with
increasing amounts of radiolabelled 125! THP. After incubation
at room temperature for 30 mm, Mab as well as antibody—bound
THP were removed from the solution by sequential addition of
rabbit anti-mouse IgG (5 jig) followed by 50 diter of a 10%
suspension of protein A containing Staphylococci. After wash-
ing of the bacterial pellet, the amounts of bound and free THP
were measured. Association constants were determined ac-
cording to Scatchard analysis.
In addition to their fine specificity for human THP, individual
Mab were analyzed by IIF on frozen kidney sections for
reactivity with rabbit or rat THP.
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Use of monoclonal antibodies to develop an lEA for THP
Using the specificity analysis described above, it was possi-
ble to develop a capture assay for THP in which a Mab of
known specificity was adsorbed to plastic wells and used to
insolubilize the THP present in the sample. The amount of THP
associated with the solid phase was assessed using a B-Mab
specific for a different epitope. The experimental conditions
used involved: 1) adsorption of the Mab (200 /.Lliter of a I
iglmliter solution in carbonate—bicarbonate buffer) on 96 well
microtiter plates for three hours at 37°C; 2) incubation of the
sample (200 piiter) for two hr at room temperature in PBST
containing 0.005% SDS; 3) incubation with B-Mab at a concen-
tration of 0.1 sg/mliter in PBST for three hr at room tempera-
ture. The various steps were separated by extensive washing in
PBST. B-Mab was detected using peroxidase labelled avidin as
described above. In routine experiments, mixtures of two
antibodies were used in steps 1 and 3, Control experiments
included the following: omission of the first Mab adsorption
step or adsorption on the wells of MOPC 173, a monoclonal IgG
devoid of anti-THP antibody activity; incubation with solutions
which did not contain THP; and incubation with B-Mab devoid
of anti-THP antibody activity.
Detection of THP in normal hutnan serum
The assay was used to demonstrate the presence of im-
munoreactive THP in fresh human serum. In initial experi-
ments, tenfold serial dilutions of normal human serum were
introduced in the capture lEA described above. In order to
confirm the specificity of the binding observed, 10 muter of
human serum were passed over a 0.5 mliter column of Sepha-
rose 4B (Pharmacia, Velizy, France) coupled to a monoclonal
anti-THP antibody (Mab 174) at a concentration of 10 mg/mliter
according to manufacturer's instructions. After thorough wash-
ing, the bound material was eluted with either alkaline buffer
[18], or SDS containing sample buffer [13] and dialysed against
distilled water. The reactive material diluted in PBST contain-
ing 0.005% SDS was assayed using various combinations of
capture and detection antibodies to determine whether the
different epitopes defined on urinary THP were detectable on
the immunoreactive material. In some experiments, in order to
assess the molecular wt of the reactive protein, the SDS—eluted
material was separated by PAGE—SDS [13] and transferred to
nitrocellulose sheets [19]. The latter were revealed with B-Mab
anti-THP followed by peroxidase labelled avidin. Peroxidase
reaction product was detected using 4-chloronaphtol. Control
experiments were performed using Sepharose 4B coupled to
MOPC 173, a monoclonal mouse lgG devoid of known antibody
specificity. The eluates were analyzed by lEA and immunoblot-
ting in the same fashion as described above. In addition, whole
human serum and urine samples were submitted to PAGE—SDS
and analyzed by immunoblotting.
Fractionation of THP from normal urine by affinity chro,na-
tography. Two hundred muter of fresh normal urine collected in
the presence of sodium azide were incubated overnight at 4°C
with 5 mli(er of S4B coupled to a Mab anti-THP. After thorough
washing, the bound material was eluted as above, concentrated











Symbols are: *BMab, biotine labelled monoclonal antibody; and
indicates complete inhibition when B-Mab is incubated with an excess
of unlabelled Mab.
Results
Production of monoclonal anti- THP antibodies
Two hundred and forty of the 300 seeded wells contained
hybrids, 43 of which secreted antibody reactive with renal
tissue. Fifteen reacted with THP by immunoenzymoassay and
indirect immunofluorescence on frozen kidney sections. The 28
remaining antibodies did not react with THP but were able to
bind various renal structures including proximal tubule brush
border.
Specificity of inonoclonal anti-THP antibodies
In order to analyze the fine specificity of the anti-THP
antibodies, the first two antibodies which were cloned, Mab 18
and Mab 174, were purified and labelled with biotin. No cross
inhibition was found when the binding of each of these B-Mab
to solid phase THP was studied in the presence of the other
Mab, thus indicating that the two Mab were directed against
distinct epitopes. At this stage, supernatants from each of the
hybrids obtained were tested for their ability to inhibit binding
of the two B-Mab. Supernatants which did not inhibit binding in
any of the two systems were considered as defining a new
epitope. The corresponding cells were cloned, and the Mab so
produced was purified, labelled with biotin and added to the
original panel. The selection process was then repeated with the
new extended panel. Table I summarizes the results of cross—
inhibition experiments. Antibodies classified as directed against
the same epitope were equally efficient to inhibit binding of the
reference B-Mab. The results initially obtained with the super-
natants were confirmed on dilutions of the corresponding
ascites, as illustrated in Figure 1. In most instances, as shown in
panel A, when Mab against distinct epitopes were compared,
inhibition was only obtained when the homologous Mab was
added to the B-Mab. Panel B illustrates the exception to this
rule: Mab 174 was able to inhibit partially the binding of B-Mab
35, whereas Mab 35 was unable to produce any inhibition of
binding of B-Mab 174. Thus complete inhibition was only
obtained when the homologous Mab was added to the B-Mab.



















Fig. 1. Analysis of the specificity of eight monoclonal anti-THP anti-
bodies, Mab 18, 33, 35, 89, 104, 174, 214, 195, directed against distinct
epitopes. 1A. Binding of biotin labelled Mab 174 was studied in the
absenceofcompetitor or in the presence of the various unlabelled Mab
(ascites diluted 10-2 to l0). Inhibition is only observed in the presence
of unlabelled Mab 174 (*). Note lack of inhibition by any of the other
Mab (0) including Mab 35 (•). lB. Binding of biotin labelled Mab 35
was studied under similar conditions. Complete inhibition is only
observed in the presence of unlabelled Mab 35 (*), but partial inhibition
is detectable with Mab 174 (•). Inhibition was not detected with any of
the other Mab (0).
Whereas all the Mab obtained were able to bind unlabelled
THP, only Mab 174, 3 and 146 could bind 125J labelled THP. The
binding data was analyzed according to Scatchard. The KA was
foundtobe2 x l07M'.
Most epitopes identified by the Mab were specific for human
THP. Mab 214 however reacted with rabbit and rat THP. Mab
195 displayed reactivity for rat THP only, Mab 89 and 174 for
rabbit THP only.
Development of an immunoenzymoassay for THP
The specificity analysis was used to set up a capture lEA.
Mab 89 and 104 were first adsorbed to plastic wells which were
subsequently incubated with THP containing solutions. After
washing the wells were incubated with B-Mab 174 and B-Mab
THP np/muter
Fig. 2. Capture immunoassay of THP. For each assay experiment, a
standardization curve was constructed by offering increasing amounts
of THP (abscissa) and measuring the optical density obtained (ordi-
nate). Each point is the mean SD of all tests performed over a period
of three months.
18. The assay was very reproducible, as shown in Figure 2
which depicts means SD of all optical densities measured
when serial twofold dilutions of THP were used to construct
standard curves over a period of three months. Specificity of
the assay was demonstrated by the lack of binding when the
anti-THP antibodies adsorbed to the wells were omitted (MOPC
173 coated wells). Sensitivity of the assay allowed detection of
THP concentrations as low as 1 nglmliter. In order to compare
reactivity of THP under various conditions, binding curves
were constructed using serial two fold dilutions of reference
purified THP and unfractionated urine. The slopes of the linear
segments (r < 0.995) were not statistically different. Intra— and
interassay coefficients of variation are respectively 10% and
13%.
Detection of THP in normal serum
As illustrated in Figure 3, the lEA was used to detect the
presence of THP in serum. Levels measured varied from 5 to 50
ng/mliter. Using various combinations of capture and detection
Mab, it was possible to demonstrate (Fig. 4) that all the five
epitopes tested, initially identified on urinary THP, were pres-
ent on the immunoreactive material prepared from serum. The
lEA was used to construct binding curves with serial twofold
dilutions of the reference THP and of the material eluted from
S4B-Mab 174. The slopes of the linear segments of the two
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Serum or urine dilution
Hg. 3. Detection of immunoreactive material in normal human serum.
Serial dilutions (10 'to 10-6) of normal serum or normal urine were
introduced in the assay system described in text, and optical densities
were measured. Reactivity was observed with normal serum (*) and
urine (0). Note lack of binding when capture antibodies are omitted(•).
curves were not statistically different. Recovery experiments
were performed in which increasing amounts of THP were
added to normal human serum. The values for measured THP
were plotted against the expected values. The regression line
obtained has an r value of 0.996 and a slope of 1.06, thus
indicating satisfactory recovery. Immunoreactive material could
not be detected in control experiments using S4B-MOPC 173.
In order to assess the molecular wt of the immunoreactive
material present in serum, material eluted from the im-
munoadsorbent with SDS buffer was submitted to PAGE—SDS,
transferred to nitrocellulose sheets and revealed using B-Mab.
Preliminary experiments demonstrated that THP prepared from
normal urine and analyzed in the same manner was reactive
with the various Mab: Mab 174 and 18 were the best reactors
and Mab 89 the poorest. As shown in Figure 5, it was possible
using B-Mab 174 to identify clearly a major immunoreactive
band comigrating with THP prepared from normal urine. No
specific binding was found when normal human serum, or
eluates from S4B-MOPC 173, were separated by PAGE—SDS
and analyzed by immunoblotting with the various B-Mab.
Preparation of urinary THP by affinity chromatography. As
shown in Figure 6, when the material eluted from Mab 174 or
Mab 18 bound to Sepharose 4B was analyzed by PAGE—SDS, a
single band comigrating with THP prepared by salt precipitation
was obtained.
Discussion
The results presented in this paper show that a variety of Mab
anti-human THP can be obtained. It is interesting to note that a
Eluate dilution
Fig. 4. Characterization ofimmunoreactive material detected in normal
serum. In a first series of experiments, assay wells were first coated
with Mab 89 and Mab 174 (0) and used to capture immunoreactive
material prepared by affinity chromatography from normal serum.
Bound material was detected with one of the following B-Mab (*) 18,
35,89 or 104. In a second series of tests, wells were coated with Mab 89
and Mab 18 (*). Bound material was detected with B-Mab 174.
Reactive material prepared from serum could be detected using all
antibody combinations. Note lack of reactivity of wells coated with
MOPC 173 (•).
number of Mab were produced to specificities unrelated to
THP. This may be in relation with the ability of THP to bind
unrelated proteins which may thus be present in the purified
preparations. The specificity studies clearly indicate that the
Mab individualize seven distinct epitopes. It cannot be ascer-
tained whether Mab 174 and Mab 35 bind closely related
epitopes with consequent steric hindrance, or whether they
recognize the same epitope but with greater affinity for Mab
174. The latter hypothesis is difficult to reconcile with the fact
that inhibition reaches a plateau at 50% when unlabelled inhib-
itor is increased over two orders of magnitude. The specificity
of the Mab provides several informations on the immunological
reactivity of THP. First, most of the Mab were unable to react
with iodinated THP, suggesting that THP may be very sensitive
to oxidative damage by chioramine T and/or introduction of
iodine in the tyrosine residues. Second, some epitopes such as
that defined by Mab 18 may be more immunogenic than others
as indicated by the isolation of five reactive clones. Third, only
a minority of Mab were able to react with antigenic determi-
nants present in several species, suggesting that they might be
less immunogenic.
The antibodies obtained were adequate to set up a capture
lEA for THP. Such an assay had not been previously reported
and was found to be as sensitive as the radioimmunoassays at






















Enzyme—linked immunoassay for THP 975
Fig. 5. Analysis of immunoreactive material present in serum. THP was
purified from urine (lane I), and serum in two different experiments
(lanes 3 and 4) by immunoaffinity chromatography on Sepharose 4B
coupled to Mab 174. Lane 2 is a control eluate prepared from normal
human serum using Sepharose 4B coupled to MOPC 173 (a control
monoclonal mouse lgG devoid of anti-THP activity) and analyzed in the
same manner. Molecular wt markers include unreduced IgG (—*), j.t
chain of 1gM (—*) and y chain of IgG (b.).
indefinite availability of the reagents should be of assistance to
standardize THP measurements already made difficult by the
variability of THP reactivity [20]. The sensitivity of the assay
was sufficient to study THP reactive material in normal human
serum. Studies using polyclonal antisera suggested that THP
was detectable in normal sera, but cross reactivity could not be
excluded. In fact, this possibility was supported by PAGE—SDS
analysis of the material purified by affinity chromatography
which demonstrated [211 the presence of numerous proteins,
none of which comigrating with purified THP. Using develop-
ments of the EIA described in this work, it could be shown that
the reactive material detectable in normal human serum shares
at least five different epitopes with urinary THP. Binding curves
obtained with serum and urine—derived material were parallel
suggesting identical reactivity. In addition, immunoblotting
experiments established that the reactive material isolated from
serum migrated on polyacrylamide gels with the expected
molecular wt for THP, thus practically excluding cross reactiv-
ity. The development of a simple and reproducible TEA should
allow further clinical studies of THP in renal pathology such as
pyelonephritis [22], tubulointerstitial diseases [24—26], tubular
obstruction [24] or transplant rejection [27].
The potential applications of the Mab reported are not limited
to assays. Using immunoadsorption techniques, it has been
possible to prepare THP by methods which do not involve high
Fig. 6. Preparation of THP from normal urine by im,nunoaffinity
chromatography. PAGE—SDS stained with Coomassie Blue. A, THP
prepared by salt precipitation; B—E, THP prepared by immunoaffinity
chromatography in four different experiments. Note identical patterns.
Symbols are as in Fig. 5.
salt precipitation, and can be performed in a few hrs. Because
the relations between structure and function are probably of
primary importance, the specificity of the Mab may be of
considerable value for further studies.
In conclusion, 15 Mab specific for TI{P have been produced.
They define at least seven different epitopes and may be used
for lEA and immunoaffinity purification.
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